Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06765317 · ClinicalTrials.gov registry record · Phase 2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
A Phase 2 study of High Grade B-Cell Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 7
- Study locations
NCT06765317: Recruiting Phase 2 study of High Grade B-Cell Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Memorial Sloan Kettering Cancer Center.
NCT06765317 is a Phase 2 study of High Grade B-Cell Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL) that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 42 participants, below the 61-participant average among 25 other High Grade B-Cell Lymphoma trials with a reported enrollment target (31% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06765317, a Phase 2 study of High Grade B-Cell Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL), is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. The treatment being tested in this study is glofitamab, polatuzumab, and obinutuzumab in combination with standard treatment (the combination of rituximab, cyclophosphamide, doxorubicin, and prednisone, or R-miniCHP).
Primary Outcome
according to the 2014 Lugano Response Criteria
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Glofitamab
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Polatuzumab
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-01-16 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
What NCT06765317 shows while recruiting
NCT06765317 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 61-participant average among 25 other High Grade B-Cell Lymphoma trials with a reported enrollment target (31% lower).
The record links to 2 conditions, with High Grade B-Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06765317 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06765317 about?
NCT06765317 is a clinical study titled "A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma". The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. The treatment being tested in this study is glofit...
What is the current status of trial NCT06765317?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2025-01-16. Estimated completion is 2028-01.
What conditions does trial NCT06765317 study?
This clinical trial studies the following conditions: High Grade B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL).
What interventions are being tested in trial NCT06765317?
The interventions under investigation include: Cyclophosphamide (DRUG), Glofitamab (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Polatuzumab (DRUG).
Who is sponsoring clinical trial NCT06765317?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06765317 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade B-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06765317's enrollment target sits among peer trials
42 9th of 25 higher than 16 of 25 other High Grade B-Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other High Grade B-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RECRUITING · Phase 2
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI